drugset
drugset / Trial / NCT00306631

A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1

NCT00306631 ↗

Phase 2 Completed 65 enrolled CASI pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase 2 study will determine the antitumor activity, based on the objective rate, of oral MKC-1, administered twice daily for 14 consecutive days every 4 weeks, in patients with advanced or metastatic breast carcinoma. The study will also evaluate the safety and response duration in patients, time to tumor progression, and overall survival in patients following MKC-1 therapy.

Timeline

Start
2006-01
Primary completion
2008-04
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MKC-1 Small molecule 30 mg Oral
Subject MKC-1 Small molecule 100 mg Oral

Indications

breast cancer